MyoKardia, Inc. (NASDAQ:MYOK) reported Q2 2017 earnings this Morning, coming in at ($0.41) per share, missing Wall Street’s estimates of ($0.37) per Share. Revenue for the quarter came in at $5.60 million missing the streets estimates of $6.73 million
Analyst Coverage For MyoKardia, Inc. (NASDAQ:MYOK)
These are 4 Buy Ratings .
The current consensus rating for MyoKardia, Inc. (NASDAQ:MYOK) is Buy (Score: 3.00) with a consensus target price of $28.00 , a potential (63.27% upside)Recent Insider Trading for MyoKardia, Inc. (NASDAQ:MYOK)
- On 8/4/2017 Anastasios Gianakakos, CEO, sold 4,300 with an average share price of $16.62 per share and the total transaction amounting to $71,466.00.
- On 7/25/2017 Anastasios Gianakakos, Insider, sold 32,988 with an average share price of $15.00 per share and the total transaction amounting to $494,820.00.
- On 3/20/2017 Anastasios Gianakakos, CEO, sold 1,412 with an average share price of $15.00 per share and the total transaction amounting to $21,180.00.
- On 3/20/2017 Jake Bauer, Insider, sold 667 with an average share price of $15.00 per share and the total transaction amounting to $10,005.00.
- On 10/3/2016 Sanofi, Major Shareholder, bought 450,000 with an average share price of $15.00 per share and the total transaction amounting to $6,750,000.00.
- On 11/3/2015 Anastasios Gianakakos, CEO, bought 1,350 with an average share price of $10.00 per share and the total transaction amounting to $13,500.00.
Recent Trading for MyoKardia, Inc. (NASDAQ:MYOK) Shares of MyoKardia, Inc. closed the previous trading session at 29.54 up +12.39 72.25% with 275,306 shares trading hands.